Literature DB >> 22761264

Nonmotor complications of Parkinson disease.

Hubert H Fernandez1.   

Abstract

Nonmotor manifestations are integral components of Parkinson disease (PD), and they often have a greater impact on disability and quality of life than the motor features that currently define the illness. Nonmotor features of PD, such as dementia, may be an intrinsic feature of the disorder and persist regardless of the medication state (ie, they continue to manifest in the "on" or "off" state); some nonmotor features, such as psychotic symptoms, may be iatrogenic complications of pharmacologic intervention for the treatment of the motor manifestations of PD. Iatrogenic complications, such as psychosis and impulse control disorders, may respond to modification of the PD treatment regimen at the risk of worsening motor symptoms. Thus, a balance must be struck between controlling nonmotor manifestations and motor features of the disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22761264     DOI: 10.3949/ccjm.79.s2a.03

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  9 in total

1.  Drug Safety Analysis in a Real-Life Cohort of Parkinson's Disease Patients with Polypharmacy.

Authors:  Saskia Müller-Rebstein; Claudia Trenkwalder; Jens Ebentheuer; Wolfgang H Oertel; Carsten Culmsee; Günter U Höglinger
Journal:  CNS Drugs       Date:  2017-12       Impact factor: 5.749

2.  MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348.

Authors:  Steven M Grauer; Robert Hodgson; Lynn A Hyde
Journal:  Psychopharmacology (Berl)       Date:  2013-10-23       Impact factor: 4.530

Review 3.  Parkinson disease: an update.

Authors:  Steven J Frucht
Journal:  Neurologist       Date:  2004-07       Impact factor: 1.398

Review 4.  Ghrelin and Neurodegenerative Disorders-a Review.

Authors:  Limin Shi; Xixun Du; Hong Jiang; Junxia Xie
Journal:  Mol Neurobiol       Date:  2016-01-26       Impact factor: 5.590

5.  Chronic salsolinol administration prevents the behavioral and neurochemical effects of L-DOPA in rats.

Authors:  Agnieszka Wąsik; Irena Romańska; Jerzy Michaluk; Lucyna Antkiewicz-Michaluk
Journal:  Neurotox Res       Date:  2015-02-25       Impact factor: 3.911

Review 6.  Psychiatric aspects of Parkinson's disease.

Authors:  Sandeep Grover; Mansi Somaiya; Santhosh Kumar; Ajit Avasthi
Journal:  J Neurosci Rural Pract       Date:  2015-01

7.  Efficient and biologically relevant consensus strategy for Parkinson's disease gene prioritization.

Authors:  Maykel Cruz-Monteagudo; Fernanda Borges; Cesar Paz-Y-Miño; M Natália D S Cordeiro; Irene Rebelo; Yunierkis Perez-Castillo; Aliuska Morales Helguera; Aminael Sánchez-Rodríguez; Eduardo Tejera
Journal:  BMC Med Genomics       Date:  2016-03-09       Impact factor: 3.063

8.  An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting.

Authors:  Nawaz Hack; Sarah M Fayad; Erin H Monari; Umer Akbar; Angela Hardwick; Ramon L Rodriguez; Irene A Malaty; Janet Romrell; Aparna A Wagle Shukla; Nikolaus McFarland; Herbert E Ward; Michael S Okun
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

Review 9.  Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications.

Authors:  Honglei Chen; Edward A Burton; G Webster Ross; Xuemei Huang; Rodolfo Savica; Robert D Abbott; Alberto Ascherio; John N Caviness; Xiang Gao; Kimberly A Gray; Jau-Shyong Hong; Freya Kamel; Danna Jennings; Annette Kirshner; Cindy Lawler; Rui Liu; Gary W Miller; Robert Nussbaum; Shyamal D Peddada; Amy Comstock Rick; Beate Ritz; Andrew D Siderowf; Caroline M Tanner; Alexander I Tröster; Jing Zhang
Journal:  Environ Health Perspect       Date:  2013-08-09       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.